Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2006-07-05
2010-08-10
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S208100, C424S232100, C536S023720, C435S236000, C435S320100
Reexamination Certificate
active
07771729
ABSTRACT:
This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.
REFERENCES:
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4722848 (1988-02-01), Paoletti et al.
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 4837028 (1989-06-01), Allen
patent: 5019369 (1991-05-01), Presant et al.
patent: 5110587 (1992-05-01), Paoletti et al.
patent: 5174993 (1992-12-01), Paoletti
patent: 5187074 (1993-02-01), Treiber et al.
patent: 5192668 (1993-03-01), Treiber et al.
patent: 5204253 (1993-04-01), Sanford et al.
patent: 5279833 (1994-01-01), Rose
patent: 5308854 (1994-05-01), Hoffman, Jr. et al.
patent: 5413999 (1995-05-01), Vacca et al.
patent: 5476874 (1995-12-01), Hungate et al.
patent: 5502060 (1996-03-01), Thompson et al.
patent: 5578597 (1996-11-01), Spector et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5663169 (1997-09-01), Young et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5714374 (1998-02-01), Arnold et al.
patent: 5736524 (1998-04-01), Content et al.
patent: 5739118 (1998-04-01), Carrano et al.
patent: 5804566 (1998-09-01), Carson et al.
patent: 5846978 (1998-12-01), Coburn et al.
patent: 5863542 (1999-01-01), Paoletti et al.
patent: 5922687 (1999-07-01), Mann et al.
patent: 7094408 (2006-08-01), Franchini et al.
patent: 2004/0033237 (2004-02-01), Franchini et al.
patent: 2004/0191272 (2004-09-01), McMichael et al.
patent: WO-9804720 (1998-02-01), None
patent: WO-9856919 (1998-12-01), None
patent: WO-01-82964 (2001-11-01), None
Cox, W. I., et al., 1993, Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein, Virol. 195:845-850.
Evans, T. G., et al., 1999, A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers, J. Infect. Dis. 180:290-298.
PCT International Search Report in related application PCT/US 01/13968, (Oct. 6, 2001),6 Pages.
Illustrated Dictionary of Immunology, Definition of “vaccine”, Cruse, J.M., et al. (eds.), CRC Press, Inc., Boca Raton, FL,(1996),p. 309.
“Animal Models”,The NIAID Division of AIDS, Science, http://www.niaid.nih.gov/daids/vaccine/animals.htm, (Archived Jan. 23, 2000),2 Pages.
“Results from EV01 HIV Vaccine Trial, London and Lausanne, Jun. 7, 2004”, (EuroVac Press Release),(Jun. 2004),2 Pages.
Abaza, M.-S. I., et al., “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin”,Journal of Protein Chemistry, 11, (1992),433-444.
Abimiku, A. G., et al., “Long-Term Survival of SIVmac251—Infected Macaques Previously Immunized with NYVAC-SIV Vaccines”,Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 15 (Supp 1), (1997),S78-S85.
ADIS International Ltd., “HIV gp120 vaccine—VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine—Genentech, HIV gp120 vaccine AIDSVAX—VaxGen, HIV vaccine AIDSVAX—VaxGen.”,Drugs R D., 4(4), (2003),249-53.
AIDS Vaccine Advocacy Coalition, “Support for the RV144 HIV vaccine trial”,Science, 305(5681), (Jul. 9, 2004),177-80.
Altman, J. D., et al., “Formation of Functional Peptide Complexes of Class II Major Histocompatibility Complex Proteins From Subunits Produced inEscherichia coli”, Pro. Natl. Acad. Sci. USA, 90, (1993),10330-10334.
Altman, J. D., et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes”,Science274, (1996),94-96.
Amara, Rama R., et al., “Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine”,Science, vol. 292, (Apr. 6, 2001),69-74.
Amara, R R., “Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques”,Virology, 334 (1), (Mar. 30, 2005),124-33.
Arp, J. , et al., “Human Immunodeficiency Virus Type 1 Envelope-Specific Cytotox T Lymphocytes Response Dynamics After Prime-Boost Vaccine Regimens With Human Immunodeficiency Virus Type 1 CanaryPox and Pseudovirions”,Viral Immunology, 12(4), (Abstract Only),(1999),1 Page.
Barnett, S. W., et al., “Prime-Boost Immunization Strategies against HIV”,AIDS Research and Human Retroviruses, 14, Supp. 3, (1998),S-299-S-309.
Bayes, M , “Gateways to clinical trials”,Methods Find Exp Clin Pharmacol., 26(4), (May 2004),295-318.
Benson, J. , et al., “Recombinant Vaccine-Induced Protection Against the Highly Pathogenic Simian Immunodeficiency Virus SIV mac251: Dependence on Route of Challenge Exposure”,Journal of Virology, 72(5), (1998),4170-4182.
Berzofsky, Jay A., et al., “Progress on new vaccine strategies against chronic viral infections”,The Journal of Clinical Investigation, vol. 114, No. 4, (Aug. 2004),450-462.
Bolesta, E , “Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens”,Virology, 332(2), (Feb. 20, 2005),467-79.
Boyer, Jean D., et al., “Vaccination of Seronegative Volunteers with a Human Immunodeficiency Virus Type 1 envlrev DNA Vaccine Induces Antigen-Specific Proliferation and Lymphocyte Production of â-Chemokines”,The Journal of Infectious Diseases, vol. 181, (2000),476-483.
Burton, D R., et al., “Public Health. A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials”,Science, 303(5656), (2004),316.
Carpenter, C. , et al., “Report of the NIH Panel to Define Principles of Therary of HIV Infection”,Morbidity and Mortality Weekly Report, 47 (RR-5), (Apr. 24, 1998),1-41.
Carroll, M. W., et al., “Host Range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus: Progagation and Generation of Recombinant Viruses in a Nonhuman Mammalian Cell Line”,Virology, 238(2), (1997),198-211.
Cohen, S. S., et al., “Pronounced Acute Immunosuppression in Vivo Mediated by HIV Tat Challenge”,Proceedings of the National Academy of Sciences of the U.S.A., 96, (Sep. 14, 1999),10842-10847.
Donnelly, J. J., et al., “DNA Vaccines”,Annu. Rev. Immunol., 15, (1997),617-648.
Dunbar, P. R., et al., “Direct Isolation, Phenotyping and Cloning of Low-Frequency Antigen-Specific Cytotoxic T Lymphocytes from Peripheral Blood”,Current Biology, 8, (1998),413-416.
Eloit, M. , et al., “Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine”,Journal of General Virology, 71(Pt. 10), (Oct. 1990),2425-2431.
Felgner, P. L., et al., “Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure”,Proc. Natl. Acad. Sci., USA, 84(21). (Nov. 1987),7413-7417.
Fuller, D. H., et al., “Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques”,Vaccine, 15(8), (1997),924-926.
Girard, M. , et al., “New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview”,C. R. Acad. Sci. Paris de la vie / Life Sci
Franchini Genoveffa
Hel Zdenek
Pavlakis George
Tartaglia James
Parkin Jeffrey S.
Sheridan Ross PC
The United States of America as represented by the Department of
LandOfFree
Methods of potentiating HIV-1-specific CD8+ immune responses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of potentiating HIV-1-specific CD8+ immune responses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of potentiating HIV-1-specific CD8+ immune responses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4150517